Facebook
Twitter
LinkedIn
ForwardPsychedelics in mental health: demystifying the ‘miracle cure’ with Marina Bayeva, MD. PhD
EI In -House Presentation
In the last two decades, psychedelics have re-emerged as promising novel agents for treatment of a broad range of mental health conditions including depression, PTSD, substance use disorders, end-of-life anxieties, eating disorders, and more. Our understanding of their putative mechanisms of action has significantly evolved as well. Several Phase II and III clinical trials of psychedelic-assisted therapy (PAT) using psilocybin and MDMA are either complete or nearing completion, with some of these therapies projected to receive FDA approval within the next couple of years. But are they ready for prime time? In this presentation, I will review the growing evidence base for use of PAT in psychiatric disorders, outline their neurobiological effects, as well as highlight unanswered questions and areas of caution. We will conclude with a discussion of how psychedelics intersect with deep exploratory work of psychoanalysis and facilitate psychological change.
Target Audience
___x___ Introductory ______ Intermediate ______ Advanced
Learning Objectives
1. Review growing evidence base for use of psychedelic-assisted psychotherapy in mental health treatment.
2. Describe neurobiological actions of psychedelic compounds, including their relevance for psychological change and psychiatric treatment.
3. Pose unanswered questions, areas of caution, and intersections between PAT and psychoanalytic work.
Marina Bayeva, MD, PhD is the Director of Psychopharmacology/Fellow in Psychiatry at the Austen Riggs Center
Austen Riggs Center Inc. adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. All those at Austen Riggs Center involved in the planning of this activity, including the presenter(s) listed above, report they have no relevant financial relationships with an ineligible company*.
The views and opinions expressed in this presentation are those of the presenter(s) and do not necessarily represent the official policy or position of the Austen Riggs Center.
* An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
ACCME - As a Jointly Accredited Organization, The Austen Riggs Center, Inc. designates this learning activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 APA
As a Jointly Accredited Organization, The Austen Riggs Center, Inc. designates this learning activity for 1.00 continuing education credit(s) (CE) for psychology. Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
Austen Riggs Center, Inc. is recognized by the New York State Education Department’s State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0115.
- 1.00 ASWB-ACE
As a Jointly Accredited Organization, The Austen Riggs Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organization, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Austen Riggs Center maintains responsibility for this. Social workers completing this Online live course will receive 1.00 continuing education credit(s).
- 1.00 Contact Hours/ ParticipationA certificate of attendance for all Learners.